An exploratory haloperidol-controlled dose-finding study of ziprasidone in hospitalized patients with schizophrenia or schizoaffective disorder

Journal of Clinical Psychopharmacology

Volumn 18, Issue 4, 1998, Pages 296-304

  Goff, Donald C ^a,g   Posever, Thomas ^b   Herz, Lawrence ^c   Simmons, Jeffrey ^d   Kletti, Nicholas ^a   Lapierre, Katherine ^e   Wilner, Keith D ^f   Law, C Gordon ^f   Ko, Grant N ^f  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b TUFTS MEDICAL CENTER   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d Tewksbury Hospital   (United States)

^e UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^f PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

^g Freedom Trail Clinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZATROPINE; HALOPERIDOL; ZIPRASIDONE;

ADULT; AKATHISIA; ARTICLE; CLINICAL TRIAL; CONFUSION; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; HYPERPROLACTINEMIA; HYPONATREMIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; SCHIZOIDISM; SCHIZOPHRENIA; SEIZURE;

ADULT; ANTIPSYCHOTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DYSKINESIA, DRUG-INDUCED; FEMALE; HALOPERIDOL; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; NEUROLOGIC EXAMINATION; PIPERAZINES; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; THIAZOLES; TREATMENT OUTCOME;

EID: 0031927910     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004714-199808000-00009     Document Type: Article

References (17)

1. Seeger TF, Seymour PA, Schmidt AW, Zorn SH, Schulz D, Lebel LA, McLean S, Howard HR, Lowe JA, Heym J. Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity. J Pharmacol Exp Ther 1995; 275:101-13.
2. 1 values. J Pharmacol Exp Ther 1989;251:238-46.
3. Altar CA, Wasley AM, Neale RF, Stone GA. Typical and atypical antipsychotic occupancy of D2 and S2 receptors: an autoradiographic analysis in rat brain. Brain Res Bull 1986;16:517-25.
4. 2 receptor antagonist, activates midbrain dopamine neurons by blocking serotonergic inhibition. Psychopharmacology (Berl) 1989;98: 45-50.
5. Lappalainen J, Hietala J, Koulu M, Syvalahti E. Neurochemical effects of chronic co-administration of ritanserin and haloperidol: comparison with clozapine effects. Eur J Pharmacol 1990;190: 403-7.
6. Saller CF, Czupryna MJ, Salama AI. 5HT2 receptor blockade by ICI 169,369 and other 5HT2 antagonists modulates the effects of D2 dopamine receptor blockade. J Pharmacol Exp Ther 1990;253: 1162-70.
7. Schremmer C, Morgenstern R, Fink H, Ott T. Atypical neuroleptics suppress dopaminergic behavioral supersensitivity. Psychopharmacology (Berl) 1990;100:399-403.
8. Tarsy D, Baldessarini RJ. The pathophysiologic basis of tardive dyskinesia. Biol Psychiatry 1970;12:431-50.
9. 2 antagonist, in electrophysiological tests predictive of antipsychotic activity. J Pharmacol Exp Ther 1989;249:673-80.
10. Wadenberg ML, Ahlenius S. Antipsychotic-like profile of combined treatment with raclopride and 8-OH-DPAT in the rat: enhancement of antipsychotic-like effects without catalepsy. J Neural Transm 1991;83:43-53.
11. Casey DE. Extrapyramidal syndromes: primate models as predictors of clinical response. Neuropsychopharmacology 1994; 10:3703.
12. Bench CJ, Lammertsma AA, Dolan RJ, Grasby PM, Warrington SJ, Gunn K, Cuddigan M, Turton DJ, Osman S, Frackowiak RSJ. Dose dependent occupancy of central dopamine D2 receptors by the novel neuroleptic CP-88,059-1: a study using positron emission tomography and 11C-raclopride. Psychopharmacology (Berl) 1993; 112:308-14.
13. Farde L, Wiesel F-A, Halldin C, Sedvall G. Central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs. Arch Gen Psychiatry 1988;45:71-6.
14. Bench CJ, Lammertsma AA, Grasby PM, Dolan RJ, Warrington SJ, Boyce M, Gunn KP, Brannick LY, Frackowiak RSJ. The time course of binding to striatal dopamine D2 receptors by the neuroleptic ziprasidone (CP-88,059-01) determined by positron emission tomography. Psychopharmacology (Berl) 1996;124:141-7.
15. Fischman AJ, Bonab AA, Babich JW, Alpert NM, Rauch SL, Elmaleh DR, Shoup TM, Williams S, Rubin RH. Positron emission tomographic analysis of central 5-hydroxytryptamine2 receptor occupancy in healthy volunteers treated with the novel antipsychotic agent, ziprasidone. J Pharmacol Exp Ther 1996;279; 939-47.
16. Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994;51:825-35.
17. Chouinard G, Jones B, Remington G, Bloom D, Addington D, MacEwan GW, Labelle A, Beauclair L, Arnott W. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 1993;13:25-40.